Emendo raises $61M series B for allele-specific gene editing

Gene editing company Emendo raised $61 million in a series B round led by Japanese biopharma AnGes. Emendo plans to partner with AnGes, which is developing gene and oligonucleotide-based therapies, on treatments for undisclosed diseases.

Emendo Biotherapeutics Inc. is developing allele-specific CRISPR gene editing technology. Its OMNI platform employs protein engineering to optimize nucleases to achieve allele specificity while maintaining high activity and avoiding off-target effects...